Producer
Alcon Inc.
Major contact-lens and eye-care maker; captive lens packaging.
3
Inputs supplied
2
Goods downstream
0
Facilities
0
Stories
What they make
3 inputs Alcon Inc. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Alcon Inc. makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Surgical (Implantables)
32%Surgical (Equipment & Instruments)
24%Vision Care (Contact Lenses)
30%Vision Care (OTC Eye Care)
14%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2024
Alcon's Silikon 1000 vitreoretinal tamponade — a 1,000 cSt purified polydimethylsiloxane (PDMS) oil injected into the eye to hold a detached retina in place — is chemically the same compound as industrial silicone sealant filler, food-grade anti-foaming agents (added to cooking oils and soft drinks), and breast implant shell fill material. Medical-grade PDMS for ophthalmology, cosmetic implant PDMS, and food-additive PDMS are produced from the same base polymer by the same silicone chemical manufacturers (Dow Corning/Dow, Shin-Etsu Chemical, Momentive) with different purification and molecular weight controls. A silicone monomer shortage or Dow production disruption would simultaneously affect retinal surgery consumables, breast implant fill, food manufacturing anti-foaming, and industrial sealant supply.
Alcon Inc. ↗Concentration2024
Alcon holds approximately 25% of the global intraocular lens (IOL) market by value, and their AcrySof aspheric IOL platform is the most widely implanted IOL in history with over 120 million implants. Cataract surgery (lens removal + IOL implant) is the most commonly performed surgical procedure in the world — approximately 25-28 million procedures annually — with ~50 million people having bilateral cataracts needing surgery. The entire cataract surgery supply chain (IOL, phacoemulsification system, OVD, surgical instruments) is dominated by Alcon, J&J Vision (AMO), and Bausch + Lomb. A supply chain disruption at Alcon's IOL manufacturing (Huntington, TX and Puurs, Belgium) would affect the most volume surgical procedure on earth.
Alcon Inc. ↗Origin2024
Alcon was founded in 1945 in Fort Worth, Texas as a small ophthalmic pharmacy by pharmacists Robert Alexander and William Conner (ALC+ON). They originally compounded eye drops for local physicians. Novartis acquired Alcon in 2010 for $49B. After years of underperformance within Novartis, Alcon was spun off as an independent Swiss-American public company in April 2019 with a ~$27B market capitalization — one of the largest healthcare spin-offs in history. The 2019 separation gave Alcon the clarity of a pure-play eye care focus, enabling distinct capital allocation from Novartis's pharma pipeline. Alcon's revenue grew from ~$7B at spin-off to ~$9.4B by 2023 as post-COVID cataract surgery backlogs cleared.
Alcon Inc. ↗